Massachusetts Life Science Company Target’s Coronavirus Detection
Rubix LS Successfully Isolated Protein Binding Receptors Previously in Ebola and Leishmaniasis, by Providing Real-Time Rapid Spectral Analysis of Key Proteins, is Actively Adapting Its Technology to Target Coronavirus WASHINGTON – Feb. 2,...
Rubix LS Expands with Asset Acquisition of Clinbotics
FOR IMMEDIATE RELEASE Rubix LS Continues 360 Degree Digital Health Campaign To Diversify Health Outcomes A respected leader in the life science and biotech product development and research sectors, Rubix LS has significantly boosted its growing digital healthcare...
Rubix LS enters into an agreement to support infectious disease data research
July 17, 2019 – Lawrence, MA – Today, Rubix LS is announcing that they’re expanding their virtual clinical trial and disease intelligence platform that will include the nations: Morocco, Kenya, Indonesia and Brazil as part of a wider United Nations,...
Rubix LS is now an SBA 8a company
July 16, 2019, Lawrence, MA – Today, Rubix LS is happy to announce that is reached SBA 8a status. Started in 1942, the SBA 8a program was developed to address vast disparities of economic opportunities, through business encouragement for minorities and key...